ReqMed Company
1
42M
1
0.04
1
- Areas of investment
Summary
ReqMed Company appeared to be the Corporate Investor, which was created in 1998.
The typical case for the fund is to invest in rounds with 8 participants. Despite the ReqMed Company, startups are often financed by Lombard Odier. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Lombard Odier, Hambrecht & Quist Capital Management. In the next rounds fund is usually obtained by Tekla Capital Management, Silicon Valley Bank, OrbiMed.
Among the various public portfolio startups of the fund, we may underline Agensys Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Pharmaceutical.
The higher amount of exits for fund were in 2007. The high activity for fund was in 2002. The fund is constantly included in less than 2 investment rounds annually. The usual things for fund are deals in the range of 10 - 50 millions dollars.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.04
- Investments by industry
- Biotechnology (1)
- Health Diagnostics (1)
- Pharmaceutical (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2002
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 24
- Avg. valuation at time of investment
- 387M
- Group Appearance index
- 1.00
- Avg. company exit year
- 10
- Avg. multiplicator
- 3.64
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Agensys | 04 Mar 2002 | Biotechnology, Health Diagnostics, Pharmaceutical | Late Stage Venture | 42M | United States, California, Santa Monica |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.